Jonathan Ticku
May 26, 2025, 07:49
Jonathan Ticku: I Had the Opportunity to Give Testimony to the FDA ODAC in Support of Daratumumab for High-Risk Smoldering Myeloma
Jonathan Ticku, Assistant Professor of Oncology at Mayo Clinic and GU Oncology Lead at Mayo Clinic Health System, shared a post on LinkedIn:
“This week I had the opportunity to give testimony to the FDA Oncologic Drugs Advisory Committee (ODAC) in support of daratumumab for high risk smoldering myeloma.
I was able to represent the perspective and challenges of practicing community hematologists and oncologists.
The ODAC voted in favor (6:2) for daratumumab use in high-risk smoldering myeloma, based on the results of the AQUILA study.”
More posts featuring Jonathan Ticku
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 26, 2025, 07:46
May 26, 2025, 07:33
May 26, 2025, 07:24
May 26, 2025, 07:18
May 26, 2025, 07:11
May 26, 2025, 06:48
May 26, 2025, 06:41